Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

Objective:Cryptococcal meningitis is one of the most important HIV-related opportunistic infections, especially in the developing world. In order to help develop global strategies and priorities for prevention and treatment, it is important to estimate the burden of cryptococcal meningitis. Design:Global burden of disease estimation using published studies. Methods:We used the median incidence rate of available studies in a geographic region to estimate the region-specific cryptococcal meningitis incidence; this was multiplied by the 2007 United Nations Programme on HIV/AIDS HIV population estimate for each region to estimate cryptococcal meningitis cases. To estimate deaths, we assumed a 9% 3-month case-fatality rate among high-income regions, a 55% rate among low-income and middle-income regions, and a 70% rate in sub-Saharan Africa, based on studies published in these areas and expert opinion. Results:Published incidence ranged from 0.04 to 12% per year among persons with HIV. Sub-Saharan Africa had the highest yearly burden estimate (median incidence 3.2%, 720 000 cases; range, 144 000–1.3 million). Median incidence was lowest in Western and Central Europe and Oceania (≤0.1% each). Globally, approximately 957 900 cases (range, 371 700–1 544 000) of cryptococcal meningitis occur each year, resulting in 624 700 deaths (range, 125 000–1 124 900) by 3 months after infection. Conclusion:This study, the first attempt to estimate the global burden of cryptococcal meningitis, finds the number of cases and deaths to be very high, with most occurring in sub-Saharan Africa. Further work is needed to better define the scope of the problem and track the epidemiology of this infection, in order to prioritize prevention, diagnosis, and treatment strategies.

[1]  J. Whitworth,et al.  Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. , 1998, International journal of epidemiology.

[2]  C. Hsiao,et al.  Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated with highly active anti-retroviral therapy. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  L. Lynen,et al.  Opportunistic infections and HIV clinical disease stage among patients presenting for care in Phnom Penh, Cambodia. , 2007, The Southeast Asian journal of tropical medicine and public health.

[4]  K. Nelson,et al.  A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  M. Oh,et al.  Spectrum of opportunistic infections and malignancies in patients with human immunodeficiency virus infection in South Korea. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Y. Germani,et al.  Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. , 2006, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[7]  N. French,et al.  Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults , 2002, AIDS.

[8]  E. Graviss,et al.  The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  P. Reiss,et al.  Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. , 2000, AIDS.

[10]  R. Hamill.  Free fluconazole for cryptococcal meningitis: too little of a good thing? , 2006, Clinical Infectious Diseases.

[11]  M. Molyneux,et al.  Bacterial meningitis in Malawian adults: pneumococcal disease is common, severe, and seasonal. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  H. Taelman,et al.  AIDS-associated cryptococcal meningitis in Rwanda (1983-1992): epidemiologic and diagnostic features. , 1999, The Journal of infection.

[13]  S. Klotz,et al.  Clinical features of HIV/AIDS patients presenting to an inner city clinic in Ho Chi Minh City, Vietnam , 2007, International journal of STD & AIDS.

[14]  T. Flanigan,et al.  Natural history of human immunodeficiency virus disease in southern India. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  R. Helbok,et al.  Chronic meningitis in Thailand. Clinical characteristics, laboratory data and outcome in patients with specific reference to tuberculosis and cryptococcosis. , 2006, Neuroepidemiology.

[16]  E. Minkoulou,et al.  Clinical and epidemiologic trends in HIV/AIDS patients in a hospital setting of Yaoundé, Cameroon: a 6-year perspective. , 2002, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[17]  M. Saag,et al.  Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. , 1997, The New England journal of medicine.

[18]  D. Legros,et al.  Systematic screening of cryptococcal antigenemia in HIV-positive adults in Uganda. , 2003, Journal of Acquired Immune Deficiency Syndromes.

[19]  R. Heyderman,et al.  Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  D. Bamberger,et al.  Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. Hakim,et al.  Cryptococcus neoformans meningoencephalitis in African children with acquired immunodeficiency syndrome , 2002, The Pediatric infectious disease journal.

[22]  M. Weinstein,et al.  Comparison of commercial kits for detection of cryptococcal antigen , 1994, Journal of clinical microbiology.

[23]  J. Becker,et al.  HIV-associated neurologic disease incidence changes: , 2001, Neurology.

[24]  Joo Sup Chung,et al.  Epidemiology and clinical features of HIV infection/AIDS in Korea. , 2003, Yonsei medical journal.

[25]  N. Wig,et al.  Spectrum of Opportunistic Infections and Profile of CD4+ Counts among AIDS Patients in North India , 2003, Infection.

[26]  R. Mugerwa,et al.  Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  Sa Azin,et al.  An overview on the 2008 UNAIDS Report on the 2008 UNAIDS Report on the Global AIDS Epidemic. , 2010 .

[28]  D. Magazi,et al.  The Impact of HIV on Meningitis as Seen at a South African Academic Hospital (1994 to 1998) , 2000, Infection.

[29]  J. Dilley,et al.  The decline of incident cases of HIV-associated neurological disorders in San Francisco, 1991-2003. , 2005, AIDS.

[30]  H. Waskin,et al.  A Randomized Trial Comparing Fluconazole with Clotrimazole Troches for the Prevention of Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection , 1995 .

[31]  R. Hayes,et al.  Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Alimuddin Zumla,et al.  Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions , 2001, Postgraduate medical journal.

[33]  K. Wannemuehler,et al.  Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence , 2006, AIDS.

[34]  G. Dore,et al.  Impact of Highly Active Antiretroviral Therapy on Individual AIDS‐Defining Illness Incidence and Survival in Australia , 2002, Journal of acquired immune deficiency syndromes.

[35]  M. Alvarez,et al.  Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy , 2006, AIDS.

[36]  D. Smith,et al.  Cryptococcal infection in an HIV-positive Ugandan population. , 2000, The Journal of infection.

[37]  D. E. Smith,et al.  A randomized, double‐blind, placebo‐controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection , 2001, HIV medicine.

[38]  A. Schuchat,et al.  Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. , 1999, The Journal of infectious diseases.

[39]  S. Mathoulin-Pélissier,et al.  Epidemiology of HIV-associated cryptococcosis in France (1985–2001): comparison of the pre- and post-HAART eras , 2004, AIDS.

[40]  K. Nelson,et al.  Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994--1998: regional variation and temporal trends. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  S. Shankar,et al.  Cryptococcosis in the immunocompromised host with special reference to AIDS. , 2000, The Indian journal of chest diseases & allied sciences.

[42]  G. Nelson,et al.  Cryptococcal pneumonia in African miners at autopsy. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[43]  M. Wolff,et al.  The Chilean AIDS Cohort: A Model for Evaluating the Impact of an Expanded Access Program to Antiretroviral Therapy in a Middle-Income Country-Organization and Preliminary Results , 2005, Journal of acquired immune deficiency syndromes.

[44]  A. Sugar,et al.  Cryptococcal pneumonia in AIDS: is cryptococcal meningitis preceded by clinically recognizable pneumonia? , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[45]  A. Mocroft,et al.  Changing incidence of central nervous system diseases in the EuroSIDA cohort , 2004, Annals of neurology.

[46]  M. Lindegren,et al.  Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  R. Helbok,et al.  Chronic Meningitis in Thailand , 2005, Neuroepidemiology.